~~<i id='196A8E1D16'><strike id='196A8E1D16'><tt id='196A8E1D16'><pre id='196A8E1D16'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：hotspot 2025-09-28 03:32:18 Page View：99

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Biogen says it will cut costs by $700 million, slash 1,000 jobs
Next article： BioMarin wins approval for gene therapy to treat hemophilia A

explore

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

US economic growth accelerated in 2nd quarter, exceeding expectations and quieting recession fears

2:04Inanundatedstockphoto,awomancarryingashoppingbasket,shopsaloneatasupermarket.STOCKPHOTO/GettyIma

New air purifier tech could be key to improving indoor air quality

AdobeUntiltheearly20thcentury,Americaregularlyexperiencedbrutallydestructiveurbanfires.Conflagration

A letter from the executive editor: STAT UnitedHealth investigation

MikeReddyforSTATIwanttobringyourattentiontoavitallyimportant investigation STAThaspublishedtoday.For